
Sign up to save your podcasts
Or
In this week's episode we’ll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.
Featured Articles:
4.1
4848 ratings
In this week's episode we’ll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.
Featured Articles:
133 Listeners
314 Listeners
26 Listeners
493 Listeners
90 Listeners
1,114 Listeners
3 Listeners
192 Listeners
349 Listeners
2 Listeners
1 Listeners
29 Listeners
169 Listeners
49 Listeners
3 Listeners